Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel

Preclinical Development of a Genetically Engineered Albumin‐Binding Nanoparticle of Paclitaxel

Nab‐paclitaxel (Abraxane), an albumin‐bound solvent‐free paclitaxel (PTX) formulation that takes advantage of the endogenous albumin transport pathway, is the current gold standard for treatment of solid tumors with PTX. However, nab‐paclitaxel has several limitations, including complex manufacturin...

Full description

Saved in:
Bibliographic Details
Main Authors: Soumen Saha, Samagya Banskota, Parisa Yousefpour, Jeffrey L. Schaal, Nikita Zakharov, Jianqiao Liu, Michael Dzuricky, Ziwei He, Stefan Roberts, Xinghai Li, Ashutosh Chilkoti
Format: Article
Language:English
Published: Wiley-VCH 2024-11-01
Series:Small Science
Subjects:
albumin‐binding domains
cancer
elastin‐like polypeptides
nab‐paclitaxel
preclinical drug development
recombinant nanoparticles
Online Access:https://doi.org/10.1002/smsc.202400153
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/smsc.202400153

Similar Items